Ninety One UK Ltd Decreases Stock Holdings in Danaher Corporation $DHR

Ninety One UK Ltd cut its stake in Danaher Corporation (NYSE:DHR) by 45.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 44,619 shares of the conglomerate’s stock after selling 37,115 shares during the quarter. Ninety One UK Ltd’s holdings in Danaher were worth $8,814,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after buying an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after acquiring an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after purchasing an additional 194,466 shares in the last quarter. Invesco Ltd. lifted its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Danaher by 4.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after acquiring an additional 163,332 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $212.92 on Thursday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.41. The company has a market cap of $152.46 billion, a P/E ratio of 45.30, a P/E/G ratio of 2.82 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average of $199.85 and a two-hundred day moving average of $197.42.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 27.23%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on DHR shares. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Wells Fargo & Company cut their price target on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a report on Wednesday, July 23rd. Barclays restated an “overweight” rating and set a $225.00 price objective (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Robert W. Baird upped their target price on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research note on Friday, July 18th. Finally, UBS Group decreased their price target on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $245.91.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.